Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
November 6, 2018 4:15 PM ESTTotal revenue of $103.0 million, a 28% increase over 2017Net product sales of $100.2 million, a 28% increase over 2017Operating earnings of $37.5 million, a 68% increase over 2017Diluted earnings per share (GAAP) of $0.52, a 79% increase over 2017Data from first three Phase III SPN-812 trials expected in December 2018Acquisition of Biscayne Neurotherapeutics, Inc. closed in October 2018Ranked #1 fastest growing pharmaceutical company worldwide per Fortune 100 fastest growing companies
ROCKVILLE, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for... More
